Abstract:Abstract Background Acral melanoma (AM) is the most common subtype in Chinese melanoma patients with a very poor prognosis. However, our understanding of the disease pathogenesis and molecular landscape is limited by the few studies that have been conducted. Here, we profiled the clinical characteristics, mutational landscapes and tumor immune microenvironment of AM patients to gain insights into disease characteristics and potential treatment strategies. Methods A total of 90 AM patients were enrolled and their tissue samples were subjected to next-generation sequencing and multiplexed immunohistochemistry tests. Kaplan–Meier curves and log-rank tests were used to analyze the prognostic potential of various genetic aberrations and immune cell compositions in AM. Results The median disease-free survival was 21.3 months and estimated median overall survival (OS) was 60 months. More advanced stages, older ages and thickness of greater than 4 mm were associated with worse prognosis in AM patients (HR = 2.57, 95% CI 1.25–5.29, p = 0.01; HR = 2.77, 95% CI 1.22–6.28, p = 0.02; HR = 3.43, 95% CI 1.51–7.82, p < 0.01, respectively), while patients who received post-surgical treatments had better survival (HR = 0.36, 95% CI 0.17–0.76, p = 0.01). The most frequently altered genes included BRAF (14.5%), KIT (16.9%), NRAS (12%), NF1 (10.8%), APC (7.2%), and ARID2 (6%). Copy number variations (CNV) were commonly found in CCND1 (19.3%), CDK4 (19.3%), MDM2 (14.5%) and FGF19 (12%). CDK4 amplifications was independently associated with shorter OS in AM patients (HR = 3.61, 95% CI 1.38–9.46, p = 0.01). CD8 + T cells (p < 0.001) and M1 macrophages (p = 0.05) were more highly enriched in the invasive margin than in the tumor center. Patients with higher levels of M1 macrophage infiltration in the invasive margin derived markedly longer OS (HR = 0.43, 95% CI 0.20–0.95, p = 0.03). Interestingly, in CDK4-amplified patients, there tended to be a low level of M1 macrophage infiltration in the invasive margin (p = 0.06), which likely explains the poor prognosis in such patients. Conclusions Our study provided a comprehensive portrait of the clinicopathological features, genetic aberrations and tumor microenvironment profiles in AM patients and identified candidate prognostic factors, which may facilitate development of additional therapeutic options and better inform clinical management of AM patients. Based on these prognostic factors, further studies should focus on enhancing the infiltration of M1 macrophages, especially in CDK4-amplified AM patients.

Prevalent Aberrations of CDK4 Pathway in Acral Melanoma and Implications for Targeted Therapy.

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Frequency of CDK2 , CCNE1 Copy Number Variation in Acral Melanoma and Implications for CDK Inhibitor in Targeted Therapy

Genetic Aberrations in the CDK4 Pathway and Association with Innate Resistance to PD-1 Blockade in Acral Melanoma.

Abstract A33: Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor survival

Prognostic Value of Genetic Aberrations and Tumor Immune Microenvironment in Primary Acral Melanoma

Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations

Original Research Palbociclib In Advanced Acral Melanoma With Genetic Aberrations In The Cyclin-Dependent Kinase 4 Pathway

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Correction To: Frequent Genetic Aberrations in the Cell Cycle Related Genes in Mucosal Melanoma Indicate the Potential for Targeted Therapy

Gene Expression Screening Identifies CDCA5 As a Potential Therapeutic Target in Acral Melanoma.

Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

Getting under the skin: The role of CDK4/6 in melanomas

Whole Genome and RNA Sequencing Reveal the Distinct Genomic Landscape of Acral Melanoma.

Data from Large-Scale Analysis of <i>kit</i> Aberrations in Chinese Patients with Melanoma

Comprehensive Genomic Profiling Reveals Distinct Patterns of Driver Mutations and Chromosomal Alterations in Acral and Mucosal Melanomas.

Palbociclib (P) In Advanced Acral Lentiginous Melanoma (Alm) With Cdk4 Pathway Gene Aberrations.